Path to Patients
CARR connects cell therapy developers to a team of experts with the sole purpose of implementing technology quickly — so you get to the clinic faster, with less risk.
The pressure
Board and investor expectations demand rapid progress to IND filing — delays burn runway and erode confidence.
Switching separation technology mid-program triggers revalidation, regulatory amendments, and months of delays.
Every equipment decision impacts burn rate. Wrong choices compound — the right platform pays for itself in avoided rework.
Moving from Phase I to commercial manufacturing introduces new failure modes. Tech transfer risk is the silent program killer.
The Path to Patients program
CARR's team works with you during PD to optimize centrifuge parameters for your specific cell type — before you lock in your process.
Demonstration units, rental programs, and buyback options remove capital barriers and de-risk your equipment investment.
The same UniFuge technology — same recipes, same consumables — scales from UFMini through U2K. No revalidation when you scale.
Full IQ/OQ, SAT, MVR, and 21 CFR Part 11 support. Our team has helped dozens of companies through IND filing.
Same technology. Same recipes. Same consumables.
From 500 mL to 2,000 L.
Why CARR
Years of centrifugation expertise
Pioneers of single-use centrifugation
Published case studies and whitepapers
Barry-Wehmiller — stability since 1885
Gamma-irradiated modules with full lot traceability. No cross-contamination risk. No cleaning validation between batches.
Programmable workflows with 21 CFR Part 11 compliance. Consistent results across operators and sites.
Cell viability above 99% for sensitive cell types. Tunable g-force and flow rate for optimized recovery.
Validated across CAR-T, TIL, NK, iPSC, gene therapy vectors, and biologics — one platform for your entire pipeline.
Dedicated application scientists, field service engineers, and process development teams across the US and Europe.
Proven integration with PBS vertical-wheel bioreactors for end-to-end iPSC and cell therapy workflows.
Scale-up success
An emerging cell therapy company needed to scale their autologous manufacturing process from Phase I (50 L) to Phase III (500 L) without revalidating their centrifugation step. Previous technology changes had cost them six months and significant capital.
Through the Path to Patients program, CARR engaged during late-stage PD. The team optimized UniFuge parameters for their specific cell type, then demonstrated linear scalability from the UFMini to the UniFuge Pilot using identical recipes and consumables.
Trusted by innovators
"This one is perfect. This would reduce our harvest time significantly. I think it fits well into the needs for a Phase III trial."
Cell Therapy Bioproduction Expert
"The UniFuge was fairly simple to use and scaled nicely from the UFMini. The whole team was able to operate it after a single training session."
Cell Therapies Bioproduction Expert
The platform
Get started
Talk to a CARR application scientist about your program timeline, technology requirements, and how the Path to Patients program can accelerate your journey to the clinic.
